Paris, Aug. 27. 2020 – SideROS raised €1 Million funding to accelerate the development of its lead candidate in cancer. Based on promising proof of concept results, SideROS will join Paris Biotech Santé incubator to initiate non-clinical pivotal investigations prior to first-in-man studies
SideROS, a French biotechnology company specialized in oncology, announced a closing of €1 M funding to tackle cancer relapse and metastasis. SideROS bridges innovative research on iron-targeting chemical compounds and drug candidate discoveries to target persister cancer cells.
The €1 M funding from private and public investment is brought half by a pool of Business Angels with international expertise in the pharmaceutical industry in the form of equity, and half by the support of Bpifrance and Région Ile-de-France in the form of grants and loans.
“This investment from qualified Business Angels and public support will allow us to accelerate our development and reach strategic milestones to move forward to pivotal regulatory toxicology studies in early 2021 and to the design of our first clinical trial planned for 2022 aiming at improving the condition of patients affected by life-threatening diseases lacking an effective treatment. We are very proud to have been selected by Paris Biotech Santé, a new step in SideROS structural development” stated Lucie Mondoulet, CEO at SideROS.